Contains Nonbinding Recommendations

Draft Guidance on Isoniazid; Pyrazinamide; Rifampin

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

Active Ingredients: Isoniazid; Pyrazinamide; Rifampin

Dosage Form; Route: Tablet; oral

Recommended Study: One study

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 50 mg; 300 mg; 120 mg
   Subjects: Males and non-pregnant, non-lactating females, general population
   Additional comments: a) Subjects with abnormal hepatic or renal function should be excluded. b) The recommended dose for the bioequivalence study should be the lowest possible based on the bioanalytical assay sensitivity but no more than five tablets due to potential adverse events.

Analytes to measure (in appropriate biological fluid): Isoniazid, pyrazinamide, and rifampin in plasma

Bioequivalence based on (90% CI): Isoniazid, pyrazinamide, and rifampin

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found on the FDA-Recommended Dissolution Methods web site, available to the public at the following location: http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units each of the test and reference products. Specifications will be determined upon review of the abbreviated new drug application.

Recommended Nov 2019